{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-013318","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.976653+00:00","generated_at":"2026-05-30T14:26:36.304618+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"MaxCyte appoints Cynthia Collins to Board; board expands to 10 members","bullets":["Cynthia Collins appointed as Class II director effective Oct 14, 2024; board expands from 9 to 10.","Collins to serve on Compensation Committee; receives 97,698 stock options (3-yr vest) and 51,679 RSUs (1-yr vest).","Over 40 years biotech experience, including CEO of Editas Medicine; boards of Poseida (PSTX), Certara (CERT), and others.","Disclosure notes past directorship at DermTech (OTC:DMTKQ) which filed Chapter 11 in June 2024; no other regulatory issues."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-013318","json":"https://secwatch.observer/filing/0001558370-24-013318.json","markdown":"https://secwatch.observer/filing/0001558370-24-013318.md","text":"https://secwatch.observer/filing/0001558370-24-013318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024013318/0001558370-24-013318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024013318/mxct-20241014x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:26:36.304618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}